<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874924</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20120304H</org_study_id>
    <nct_id>NCT02874924</nct_id>
  </id_info>
  <brief_title>Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly</brief_title>
  <official_title>Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability to mount an effective immune response declines with age, leaving the elderly
      increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug
      to prevent transplant rejection, increases the lifespan and healthspan of mice and
      ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in
      laboratory animals. Investigators are conducting a translational trial to test whether
      rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhibition of the mTOR pathway by rapamycin (RAPA), an immunosuppressive drug used as adjunct
      therapy in preventing solid organ allograft rejection, enhances longevity in mice.
      Importantly, RAPA was efficacious even when initiated in relatively old animals. Thus, it has
      been suggested that RAPA could be used therapeutically in humans to slow age-associated
      pathologies. Indeed, improvements in cognition, control of tumorigenesis, and enhancing
      certain aspects of immunity have been demonstrated in RAPA treated murine models. Moreover,
      long-term RAPA delivery in older mice is associated with changes in immune reactivity not
      evident in younger animals. Investigators propose to expand to a larger cohort of older
      humans to test the hypothesis that RAPA treatment, even in very old individuals, will result
      in simultaneous improvement in systems known to be negatively affected by aging.
      Investigators will focus on the immune system, cognition, and physical parameters of healthy
      aging, such as walking speed. Investigators will recruit healthy volunteers, aged 75-95
      years, and randomize them to either RAPA or placebo, controlling for gender, ethnicity, and
      age. These groups will be used to address the following specific aims: Aim 1. Assess general
      parameters of immune health before and after RAPA treatment; these include serum inflammatory
      cytokines, PBMC subsets (naïve vs memory T cells, TREGS, etc.), and polyclonal T cell
      activation potential. Aim 2. Test the effects of RAPA treatment on responsiveness to a
      vaccine challenge; both B cell (antibody) and T cell responses will be assessed. Aim 3.
      Correlate immune function rejuvenation with cognitive and physical function measures in
      subjects treated with RAPA or placebo. Aim 4. Collect pilot data on effect of RAPA on
      cardiovascular function. Cognition will be assessed by three different testing tools (EXIT25,
      SLUMS, and TAPS). Physical performance will be measured by grip strength and 40 foot timed
      walks, parameters known to correlate with healthy aging. Measures of cardiovascular function
      (Substudy D) using MRI of the heart to evaluate diastolic function and brain MRI to analyze
      cerebral blood flow, with measures of pulse wave velocity and endothelial function using
      laser doppler flowmetry will be performed. In addition to scoring positive outcomes,
      investigators will assess whether there are adverse changes in clinical laboratory tests that
      could compromise the safe use of RAPA therapeutically in older individuals. The long-term
      goal is to assess whether RAPA is safe to use in an elderly population, while also being
      efficacious in slowing, or even reversing, the aging process.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological Responses</measure>
    <time_frame>8 weeks</time_frame>
    <description>T cell function measured by number of T cells per millimeter cubed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>walking speed: Timed 40-foot walk: each participant will perform 3 walks (timed with a stopwatch) at their preferred walking speed over a measured 40-foot path. Results will be averaged for analysis. The faster the walking speed the better the performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Executive Interview (EXIT25) - This test is a brief bedside test that consists of 25 items measuring abilities that include:
Executive functioning, Motor sequencing, Spoken alternate sequencing, Verbal fluency, Design fluency, Persistence, Resistance to interference, Reflexes Scoring directions are listed under each of the 25 portions of this test. For each section, the client is given a score of a 0, 1, or 2. A score &quot;0&quot; indicates no impairment, a score of &quot;1&quot; indicates some impairment, and a score of &quot;2&quot; indicates severe impairment. Directions for what qualifies as each score are listed under each section. The points are totaled and criteria are given for severe, moderate, and no impairment. Minimum score is -0- and maximum is 50. A score of 15 or below indicates normal executive functioning, a score of above 15 indicates moderate to severe impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular Effect</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pulse Wave Velocity is measured using an Electrocardiogram (ECG)</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of Diastolic Filling</measure>
    <time_frame>8 weeks</time_frame>
    <description>Diastolic function was assessed using Magnetic Resonance Imaging (MRI) of the heart to measure the diastolic filling of the heart in participants in the open label rapamycin group.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin 1mg taken once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamycin Alone - Cardiovascular Effects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No placebo control; Rapamycin 1mg once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>treatment</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>No placebo control in this substudy group</description>
    <arm_group_label>Rapamycin Alone - Cardiovascular Effects</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: age 70-95

          -  participants will be in good health with all chronic diseases (hypertension, coronary
             artery disease, etc.) clinically stable.

          -  participants must have adequate cognitive function to be able to give informed
             consent. This will be established by enrolling participants with CLOX 1 scores of ≥10.

        Exclusion Criteria:

          -  unstable ischemic heart disease

          -  clinically significant pulmonary disease

          -  history of immunodeficiency or receiving immunosuppressive therapy

          -  history of a coagulopathy or receiving a medical condition requiring anticoagulation

          -  an estimated glomerular filtration rate of &lt;30ml/min

          -  uncontrolled hypercholesteremia &gt;350mg/dl;

          -  uncontrolled hypertriglyceridemia &gt;500mg/dl

          -  diabetes

          -  history of skin ulcers or poor wound healing

          -  smoking

          -  liver disease

          -  treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Kellogg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <results_first_submitted>October 16, 2018</results_first_submitted>
  <results_first_submitted_qc>November 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2018</results_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geriatrics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02874924/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rapamycin</title>
          <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
        </group>
        <group group_id="P3">
          <title>Rapamycin Alone - Cardiovascular Effects</title>
          <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rapamycin</title>
          <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
        </group>
        <group group_id="B3">
          <title>Rapamycin Alone - Cardiovascular Effects</title>
          <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Only participants age 70 years or older were eligible</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age, 70 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunological Responses</title>
        <description>T cell function measured by number of T cells per millimeter cubed.</description>
        <time_frame>8 weeks</time_frame>
        <population>In the cardiovascular arm, no T cell function was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin</title>
            <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin Alone - Cardiovascular Effects</title>
            <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological Responses</title>
          <description>T cell function measured by number of T cells per millimeter cubed.</description>
          <population>In the cardiovascular arm, no T cell function was analyzed.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="3.82"/>
                    <measurement group_id="O2" value="11.24" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot study, therefore, no power calculation available.</non_inferiority_desc>
            <p_value>0.56</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.48</ci_lower_limit>
            <ci_upper_limit>4.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Performance</title>
        <description>walking speed: Timed 40-foot walk: each participant will perform 3 walks (timed with a stopwatch) at their preferred walking speed over a measured 40-foot path. Results will be averaged for analysis. The faster the walking speed the better the performance.</description>
        <time_frame>8 weeks</time_frame>
        <population>Walking speed was not analyzed in the cardiovascular group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin</title>
            <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin Alone - Cardiovascular Effects</title>
            <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Performance</title>
          <description>walking speed: Timed 40-foot walk: each participant will perform 3 walks (timed with a stopwatch) at their preferred walking speed over a measured 40-foot path. Results will be averaged for analysis. The faster the walking speed the better the performance.</description>
          <population>Walking speed was not analyzed in the cardiovascular group.</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="1.12"/>
                    <measurement group_id="O2" value="7.17" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function</title>
        <description>The Executive Interview (EXIT25) - This test is a brief bedside test that consists of 25 items measuring abilities that include:
Executive functioning, Motor sequencing, Spoken alternate sequencing, Verbal fluency, Design fluency, Persistence, Resistance to interference, Reflexes Scoring directions are listed under each of the 25 portions of this test. For each section, the client is given a score of a 0, 1, or 2. A score &quot;0&quot; indicates no impairment, a score of &quot;1&quot; indicates some impairment, and a score of &quot;2&quot; indicates severe impairment. Directions for what qualifies as each score are listed under each section. The points are totaled and criteria are given for severe, moderate, and no impairment. Minimum score is -0- and maximum is 50. A score of 15 or below indicates normal executive functioning, a score of above 15 indicates moderate to severe impairment.</description>
        <time_frame>8 weeks</time_frame>
        <population>EXIT25 was not collected or analyzed in cardiovascular group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin</title>
            <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin Alone - Cardiovascular Effects</title>
            <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function</title>
          <description>The Executive Interview (EXIT25) - This test is a brief bedside test that consists of 25 items measuring abilities that include:
Executive functioning, Motor sequencing, Spoken alternate sequencing, Verbal fluency, Design fluency, Persistence, Resistance to interference, Reflexes Scoring directions are listed under each of the 25 portions of this test. For each section, the client is given a score of a 0, 1, or 2. A score &quot;0&quot; indicates no impairment, a score of &quot;1&quot; indicates some impairment, and a score of &quot;2&quot; indicates severe impairment. Directions for what qualifies as each score are listed under each section. The points are totaled and criteria are given for severe, moderate, and no impairment. Minimum score is -0- and maximum is 50. A score of 15 or below indicates normal executive functioning, a score of above 15 indicates moderate to severe impairment.</description>
          <population>EXIT25 was not collected or analyzed in cardiovascular group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="4.52"/>
                    <measurement group_id="O2" value="6.92" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiovascular Effect</title>
        <description>Pulse Wave Velocity is measured using an Electrocardiogram (ECG)</description>
        <time_frame>8 weeks</time_frame>
        <population>Due to technical problems with equipment, data were not captured for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin</title>
            <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin Alone - Cardiovascular Effects</title>
            <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Effect</title>
          <description>Pulse Wave Velocity is measured using an Electrocardiogram (ECG)</description>
          <population>Due to technical problems with equipment, data were not captured for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Volume of Diastolic Filling</title>
        <description>Diastolic function was assessed using Magnetic Resonance Imaging (MRI) of the heart to measure the diastolic filling of the heart in participants in the open label rapamycin group.</description>
        <time_frame>8 weeks</time_frame>
        <population>Cardiovascular effects were not measured in the Rapamycin versus placebo group, only open label rapamycin group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin</title>
            <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin Alone - Cardiovascular Effects</title>
            <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Diastolic Filling</title>
          <description>Diastolic function was assessed using Magnetic Resonance Imaging (MRI) of the heart to measure the diastolic filling of the heart in participants in the open label rapamycin group.</description>
          <population>Cardiovascular effects were not measured in the Rapamycin versus placebo group, only open label rapamycin group.</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="132.84" spread="26.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks per subject</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rapamycin</title>
          <description>Rapamycin 1mg taken once daily for 8 weeks
Rapamycin: treatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo taken once daily for 8 weeks
Placebo: control</description>
        </group>
        <group group_id="E3">
          <title>Rapamycin Alone - Cardiovascular Effects</title>
          <description>No placebo control; Rapamycin 1mg once daily for 8 weeks
Rapamycin: No placebo control in this substudy group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rash of face</sub_title>
                <description>Acneform rash</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dean L. Kellogg, Jr, MD, PhD</name_or_title>
      <organization>Univ TX Health Science Center San Antonio</organization>
      <phone>2106175197</phone>
      <email>kelloggd@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

